Objectives: Monocytes and macrophages produce interleukin-1β by inflammasome activation which involves adenosine triphosphate release, pannexin-1 channels, and P2X7 receptors. However, interleukin-1β can also be produced in an inflammasome-independent fashion. Here we studied if this mechanism also involves adenosine triphosphate signaling and how it contributes to inflammasome activation. Design: In vitro studies with human cells and randomized animal experiments. Setting: Preclinical academic research laboratory. Subjects: Wild-type C57BL/6 and pannexin-1 knockout mice, healthy human subjects for cell isolation. Interventions: Human monocytes and U937 macrophages were treated with different inhibitors to study how purinergic signaling contributes to toll-like receptor-induced cell activation and interleukin-1β production. Wild-type and pannexin-1 knockout mice were subjected to cecal ligation and puncture to study the role of purinergic signaling in interleukin-1β production and host immune defense. Measurements and Main Results: Toll-like receptor agonists triggered mitochondrial adenosine triphosphate production and adenosine triphosphate release within seconds. Inhibition of mitochondria, adenosine triphosphate release, or P2 receptors blocked p38 mitogen-activated protein kinase and caspase-1 activation and interleukin-1β secretion. Mice lacking pannexin-1 failed to activate monocytes, to produce interleukin-1β, and to effectively clear bacteria following cecal ligation and puncture. Conclusions: Purinergic signaling has two separate roles in monocyte/macrophage activation, namely to facilitate the initial detection of danger signals via toll-like receptors and subsequently to regulate nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 3 inflammasome activation. Further dissection of these mechanisms may reveal novel therapeutic targets for immunomodulation in critical care patients. (Crit Care Med 2018; 46:e1183-e1189) 
rich repeat and pyrin domain containing 3 (NLRP3) inflammasome activation (4) (5) (6) . The NLRP3 inflammasome activates caspase-1, which cleaves the precursor molecule pro-IL-1β to the active cytokine (2, 7, 8) .
LPS is known to activate the NLRP3 inflammasome via a two-step cascade (7) . In a priming phase, TLR4-induced nuclear factor κ-light-chain-enhancer of activated B cells signaling causes the transcription of gene products that are needed for NLRP3 inflammasome assembly and pro-IL-1β production. In a second phase, the NLRP3 inflammasome assembles and converts procaspase-1 to active caspase-1 that generates IL-1β. Recent work has shown that additional pathways can cause NLRP3 inflammasome activation (8) (9) (10) . These NLRP3 inflammasome activation pathways involve P2X7 receptors, pannexin-1 (panx1) channels, and adenosine triphosphate (ATP) release into the extracellular space (8, (11) (12) (13) (14) . In addition, monocytes can produce IL-1β independently from inflammasome activation (15) . However, the mechanisms by which ATP signaling regulates IL-1β production in response to LPS have remained only partially defined and were the objective of this study (7) .
Here we show for the first time that TLR agonists trigger rapid ATP release within seconds of TLR stimulation, that mitochondria produce the ATP that is released, and that the released ATP initiates purinergic signaling events needed for cell activation. Our findings show that purinergic signaling has at least two roles in monocyte/macrophage activation, namely to facilitate the initial detection of danger signals and to coordinate subsequent signaling pathways that lead to inflammasome activation and IL-1β secretion.
MATERIALS AND METHODS

Materials
A human TLR1-9 agonist kit (Fig. 1A) was from Invivogen (San Diego, CA). The mimetic pannexin-1 inhibitory peptide 10 panx1 was from R&D Systems (Minneapolis, MN) and Rhod-2 AM from Thermo Fisher Scientific (Waltham, MA). Antibodies: mouse anti-human CD14 FITC (clone M5E2, BD Biosciences, San Jose, CA), rabbit anti-human phospho-p38 MAPK, anti-caspase-1 (Cell Signaling, Danvers, MA), rabbit anti-human p38 MAPK (Santa Cruz, Santa Cruz, CA), goat anti-rabbit IgG-peroxidase. All other reagents: from Sigma-Aldrich (St. Louis, MO) unless otherwise stated.
Human Blood Monocytes
The Institutional Review Board approval was obtained from Beth Israel Deaconess Medical Center (BIDMC) for studies using human subjects; protocols were in accordance with the Declaration of Helsinki. Venous blood was collected from healthy volunteers, and peripheral blood mononuclear cells (PBMCs) were isolated using Ficoll-Paque (GE, Piscataway, NJ). Monocyte isolation by plastic adherence: PBMCs were suspended in RPMI-1640 media (ATCC, Manassas, VA), placed in 96-well flat-bottom culture dishes (Celltreat, Pepperell, MA) for 2 hours at 37°C, and nonadherent cells were removed by washing with fully supplemented RPMI-1640 (10% heatinactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin; Thermo Fisher Scientific). Viability was assessed with propidium iodide staining (1.5 μM for 10 min) and flow cytometry or fluorescence microscopy.
U937 Monocyte Cell Culture and Differentiation
U937 cells (ATCC) were maintained in fully supplemented RPMI-1640 at 37°C in 5% CO 2 . Prior to use, cells were differentiated to macrophages with phorbol myristate acetate (10 ng/mL) for 48 hours (16) .
ATP Measurements
Cells were incubated in fresh culture medium at 37°C for 30 minutes, treated with different inhibitors for 5 minutes, stimulated with LPS or other TLR agonists, and reactions were stopped on ice. Supernatants were obtained by centrifugation (5 min, 400 × g, 0°C) and ATP was measured with a bioluminescence assay kit (Invitrogen, Carlsbad, CA). Pannexin-1 (panx1) channels facilitate adenosine triphosphate (ATP) release in response to toll-like receptor (TLR) stimulation. A, U937 macrophages were pretreated with the panx1 inhibitor carbenoxolone (CBX) (100 μM) or not for 5 min and then stimulated with different TLR ligands (TLR1/2: Pam3CysSerLys4, 1 μg/mL; TLR2: heat-killed Listeria monocytogenes, 108 cells/mL; TLR3: polyriboinosinic:polyribocytidylic acid (poly(I:C)), 10 μg/mL; TLR4: lipopolysaccharides (LPS), 10 ng/mL; TLR5: flagellin, 10 μg/mL; TLR6/2: synthetic lipopeptide Pam2CGDPKHPKSF derived from Mycoplasma salivarium, FSL-1, 1 μg/mL; TLR7: Imiquimod, 10 μg/mL; TLR8: single-stranded RNA ssRNA40, 10 μg/ mL; TLR9: oligodeoxynucleotides 2006, 5 μM). After stimulation for 5 s, reactions were stopped by chilling in an ice bath. Cells were removed by centrifugation and ATP concentrations in the supernatants determined with a luciferase assay kit. B, U937 macrophages were stimulated with LPS (10 ng/mL) and ATP concentrations in the cell culture supernatants were measured at the indicated time points. C and D, Primary human monocytes or U937 macrophages were pretreated for 5 min with the panx1 inhibitors CBX (100 μM) or the mimetic pannexin-1 peptide 10 panx1 (100 μM), stimulated with the indicated LPS concentrations, and ATP release was assessed after 5 s. Data shown are mean values ± sd of n ≥ 3 independent experiments; *p < 0.05 vs unstimulated controls; #, §p < 0.05 vs stimulated cells in the absence of panx1 inhibitors. Immunoblotting Immunoblotting was performed as described previously (18) . MAPK p38 and caspase-1 activation were assessed using antibodies that recognize the phosphorylated form of MAPK p38 and the active p20 caspase-1 fragment, respectively. Pro-IL-1β levels were measured in cell lysates using mouse-anti human IL-1β antibody (R&D Systems). Total MAPK p38 was assessed as loading control.
Mitochondrial
Determination of IL-1β Levels
IL-1β was determined with enzyme-linked immunosorbent assay kits (R&D Systems).
Mouse Model of Sepsis and Infection
Animal experiments were approved by the Institutional Animal Care and Use Committees of BIDMC and done as per NIH guidelines. C57BL/6 wild-type (WT) mice were from Charles River Laboratories (Wilmington, MA). Panx1 knockout mice were from The Knockout Mouse Project Center for Comparative Medicine (University of California, Davis, CA) and backcrossed into a C57BL/6 background. Polymicrobial sepsis was induced by cecal ligation and puncture (CLP) as described (19) . In some experiments, mice received intraperitoneal injections of live Escherichia coli (10 8 ) and remaining bacteria in the peritoneal cavity were determined after 2 hours (19) . Monocyte activation was assessed by flow cytometry using anti-CD11b and anti-Ly6C antibodies. Briefly, blood was collected by cardiac puncture, RBCs lysed, leukocytes treated with Fc blocker (BD Biosciences), and labeled with PE-anti-Gr1 (clone: RB6-8C5), PerCP-anti-Ly6C (clone: HK1.4), and APC-anti-CD11b (clone: M1/70) antibodies (Thermo Fisher Scientific). Monocytes were identified by gating on Gr1
+ cells.
Statistical Analysis
Values are expressed as mean ± sd. Unpaired two-tailed Student's t tests were used to compare two groups, and one-way analysis of variance was used for multiple group comparisons. Differences were considered significant at p value of less than 0.05.
RESULTS
TLR Receptor Stimulation Triggers Rapid ATP Release via panx1 Channels
Extracellular ATP release from damaged tissues has been shown to stimulate P2X7 receptors and to induce inflammasome activation and IL-1β secretion (13, 14) . Most previous studies evaluated ATP release hours after cell stimulation at times that coincide with NLRP3 inflammasome activation long after TLR stimulation with LPS or other agonists. However, little is known about whether ATP release is needed for the initial steps associated with TLR stimulation. We used primary human monocytes freshly isolated from the peripheral blood of healthy donors and human U937 cell cultures that were differentiated to macrophages as previously described (16) . Measuring ATP concentrations in the cell supernatant using an ATP bioluminescence assay, we found that both cell types released significant amounts of ATP within 5 seconds of TLR stimulation with most TLR agonists studied ( (Fig. 1, C  and D) . These data indicate that panx1-dependent ATP release is an early signaling event that precedes IL-1β secretion in TLR responsive monocytes and macrophages.
Purinergic Signaling is Required for TLR4-Induced p38 MAPK Activation IL-1β expression requires p38 MAPK activation, which is a hallmark of the cell signaling pathway triggered by LPS (20, 21) . We studied whether ATP signaling is necessary for LPSinduced p38 MAPK activation in U937 macrophages. We found that LPS but also ATP, uridine-5'-triphosphate (UTP), and the nonhydrolyzable ATP analog adenosine 5′-(3-thiotriphosphate) activated p38 MAPK in 30 seconds (Fig. 2A) . LPS and UTP had similar effects. Because UTP and ATP are both agonists of P2Y2 receptors, these findings suggest that autocrine stimulation of P2Y2 receptors is involved in the response of cells to LPS. This notion is supported by the finding that inhibition of LPS-induced ATP release with CBX or activation of P2 receptors with the antagonist suramin prevented p38 MAPK activation in response to LPS ( Fig. 2B; and 
Mitochondria Fuel the panx1/ATP/P2 Receptor Signaling Mechanisms Triggered by LPS
Because LPS-induced cell activation required rapid ATP release, we tested whether mitochondria are needed to produce the ATP that is released. Mitochondria produce ATP by oxidative phosphorylation, which requires the influx of Ca 2+ into mitochondria (22, 23) . Using the mitochondrial Ca 2+ probe Rhod-2, we found that mitochondrial Ca 2+ uptake increased immediately after the stimulation of U937 macrophages with LPS ( Supplemental Fig. 2, C and D (Fig. 2D) . Pretreatment of U937 cells with CBX, suramin, or CCCP also impaired mitochondrial Ca 2+ uptake in response to LPS, which suggests that TLR4-induced ATP release and autocrine stimulation of P2 receptors enhance mitochondrial activity in LPS-stimulated cells ( Fig. 2C; and Supplemental Video 3, Supplemental Digital Content 5, http://links.lww.com/CCM/E28-legend, Supplemental Digital Content 9, http://links.lww.com/CCM/ E32). Similar to U937 macrophages, inhibitors of mitochondrial ATP synthesis impaired ATP release from LPS-stimulated human monocytes (Fig. 3, A and B) . None of the mitochondrial inhibitors tested affected cell viability for up to 24 hours (Supplemental Fig. 3 , Supplemental Digital Content 6, http:// links.lww.com/CCM/E29; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/E32). Taken together, our findings show that mitochondria have a central role in the activation of monocytes and macrophages by LPS and that an initial burst of ATP release in response to TLR4 stimulation promotes an autocrine feed-forward signaling mechanism that upregulates mitochondrial activity.
Purinergic Signaling is Required for LPS-Induced Caspase-1 Activation and IL-1β Secretion
Initial purinergic signaling generates ATP needed for TLR signaling. In addition, it likely also provides the ATP to support subsequent cell activation processes such as NLRP3 inflammasome activation and IL-1β production. IL-1β secretion Figure 2 . Autocrine purinergic signaling is required for lipopolysaccharides (LPS)-induced p38 mitogen-activated protein kinase (MAPK) activation and for the up-regulation of mitochondrial activity. A, U937 macrophages were stimulated with LPS (1 μg/mL), adenosine triphosphate (ATP) (100 μM), uridine-5'-triphosphate (UTP) (100 μM), or the nonhydrolyzable ATP analog adenosine 5'-(3-thiotriphosphate) (ATPγS) (100 μM). Reactions were stopped after 30 s by chilling in an ice bath, and p38 MAPK activation was assessed by immunoblotting and comparing the ratio between phosphorylated p38 MAPK and total p38 MAPK (loading control). B, U937 macrophages were pretreated with the indicated concentrations of CBX for 5 min, stimulated with LPS (1 μg/mL) for 30 s, and p38 MAPK activation was determined. C, U937 cells were plated onto glass coverslips, differentiated, and loaded with the mitochondrial Ca2+ probe Rhod-2-AM. U937 macrophages were stimulated with LPS (10 ng/mL) with or without inhibitors that block ATP release (carbenoxolone [CBX], 100 μM), mitochondrial ATP production (carbonyl cyanide m-chlorophenyl hydrazone [CCCP], 10 μM), or P2 receptor activation (suramin, 100 μM). Rhod-2 fluorescence was recorded and plotted over time. Data shown are mean values ± sem of n ≥ 15 cells derived from three independent experiments. D, U937 macrophages were pretreated with CBX (100 μM) or CCCP (10 μM) for 5 min, stimulated with LPS (10 ng/mL) for 5 s, and ATP release was determined as described above. Data in (A, B, and D) represent mean values ± sd of n = 3 independent experiments; *p < 0.05 vs unstimulated controls; #p < 0.05 vs LPS-stimulated control without inhibitors.
Critical Care Medicine www.ccmjournal.org e1187 requires activation of caspase-1 and the formation of an active p20 caspase-1 fragment (24, 25) . LPS-induced rapid and prolonged caspase-1 activation in U937 macrophages (Fig. 3C) . Caspase-1 activation was blocked by inhibitors of mitochondrial ATP synthesis (CCCP, oligomycin, rotenone, or KCN) or panx1-induced ATP release (CBX, 10 panx1), and by nonselective P2 (suramin) and selective P2X7 (A438079) receptor antagonists (Fig. 3, C and D) . Similarly, blocking mitochondria, ATP release, or P2 receptors dose-dependently impaired LPS-induced IL-1β secretion from primary human monocytes (Fig. 4) . In summary, our results show that blocking ATP release or P2 receptor signaling inhibits early events occurring within seconds of LPS stimulation, such as p38 MAPK activation, as well as later events such as transcription of pro-IL-1β and caspase-1 activation, which precede IL-1β release (Fig. 5A ). These findings demonstrate that TLR4-induced mitochondrial ATP synthesis and autocrine purinergic signaling are required for the initial activation of monocytes and macrophages and for subsequent functional responses that lead to IL-1β production via inflammasome-dependent or independent pathways.
Purinergic Signaling is Required for Monocyte Activation in Sepsis and Antimicrobial Host Defense
LPS increases IL-1β production in response to infection and sepsis (26) . We subjected WT and panx1 knockout mice to CLP as previously described, resulting in severe bacteremia (19) . CLP triggered IL-1β production in 1 hour and caused polarization of monocytes to an inflammatory M1 phenotype characterized by increased CD11b and Ly6C expression ( Fig.  5A; and Supplemental Fig. 4 , Supplemental Digital Content 7, http://links.lww.com/CCM/E30-legend, Supplemental Digital Content 9, http://links.lww.com/CCM/E32) (27) . Panx1 knockout mice failed to produce IL-1β and to activate monocytes in response to CLP and were less capable than WT mice of coping with bacteria following E. coli injection (Fig. 5B) and CLP-induced bacteremia (19) . These findings demonstrate that monocytes depend on panx1-induced ATP release to recognize danger cues such as LPS and to orchestrate the necessary inflammatory response that is required to protect the host from infections.
DISCUSSION
Our findings indicate that cellular ATP release is essential for the detection of LPS and other danger molecules by monocytes and macrophages. Mitochondria fuel the initial panx1/ATP/P2 . Then cells were stimulated with LPS (10 ng/mL) for 5 s, and ATP concentrations in the supernatants were determined as described in Figure 1 . Data shown are means ± sd of n = 6 (A) or n = 3 (B) independent experiments; #p < 0.05 compared with LPS-stimulated controls. C, U937 macrophages were stimulated with LPS (1 μg/mL) for the indicated times. Then caspase-1 activation levels were assessed using immunoblotting and antibodies that recognize activated caspase-1 (p20 subunit). D, U937 macrophages were pretreated or not with the mitochondrial inhibitors CCCP (10 μM), rotenone (10 μM), oligomycin (10 μM) or potassium cyanide (KCN) (500 μM), the pannexin-1 channel blockers carbenoxolone (CBX) (100 μM) or the mimetic pannexin-1 peptide 10panx1 (100 μM), or the P2 receptor inhibitors suramin (pan-P2 receptors; 100 μM) or A438079 (P2X7 receptors; 10 μM) for 15 min. Then cells were stimulated with LPS (1 μg/mL) for 2 hr and caspase-1 activity was measured. Total p38 mitogen-activated protein kinase was assessed as loading control. Data shown are mean values ± sd of n = 3 separate experiments; *p < 0.05 vs unstimulated negative controls; #p < 0.05 vs LPS-stimulated positive control. receptor signaling pathways triggered by TLR agonists as well as subsequent signaling steps that induce IL-1β secretion from stimulated cells (Supplemental Fig. 5 , Supplemental Digital Content 8, http://links.lww.com/CCM/E31; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/E32). NLRP3 inflammasome activation and IL-1β secretion are known to involve extracellular ATP, panx1, and P2X7 receptors (10, 28) . However, the purinergic signaling events upstream of inflammasome activation have not been previously defined (7) .
Here we show that TLR4 stimulation triggers rapid ATP release, which extends previous reports that ATP release contributes to inflammasome activation (12, 13, (29) (30) (31) . Previous studies focused on ATP release as a trigger of inflammasome activation. In particular, external ATP at millimolar concentrations was shown to induce inflammasome activation by inducing P2X7 receptors to form large pores and causing mitochondrial disruption and pyroptosis (7) . By contrast, little is known about ATP release as an upstream signaling event that facilitates cell activation. Here we show, to our knowledge for the first time, that mitochondria rapidly generate the ATP that is released and that a panx1/ATP/P2Y2 receptor signaling axis is required for TLR4 signal amplification. We propose that monocytes and macrophages use this initial panx1/ATP/P2Y2 trigger mechanism to detect danger signals and to initiate NLRP3 inflammasome priming by generating pro-IL-1β and other building blocks that are needed for the assembly of the NLRP3 inflammasome complex. Activation of NLRP3 involves a second purinergic signaling mechanism via the better-known panx1/ATP/P2X7 receptor axis. Monocytes seem to need both purinergic signaling mechanisms to detect microbial dangers, to produce IL-1β, and to cope with invading microorganisms (Supplemental Fig.  5 , Supplemental Digital Content 8; legend, Supplemental Digital Content 9, http://links.lww.com/CCM/E32).
Our previous work has shown that similar purinergic signaling mechanisms regulate the functions of T cells and neutrophils (18, (32) (33) (34) . Taken together, our findings demonstrate that mitochondria and autocrine purinergic signaling mechanisms regulate diverse aspects of the innate and adaptive immune responses to infections. A role for mitochondria in inflammasome activation has been previously recognized, but the underlying mechanisms have remained unclear (35) (36) (37) . Our current findings indicate that one of the roles of mitochondria is to generate ATP to initiate the purinergic signaling mechanism by which cells detect TLR agonists and respond with NLRP3 inflammasome activation if needed. This interpretation is supported by a recent report showing that mitochondrial function is required for NLRP3 inflammasome activation by extracellular ATP (38) .
Although NLRP3 is perhaps the best-characterized inflammasome, other canonical and noncanonical inflammasome pathways involving caspase-11, have been recently described (9, 10, 39, 40) . Future studies will be needed to assess whether autocrine purinergic signaling mechanisms are involved in these signaling pathways and how they contribute to host defense and inflammation in critical care patients.
TLR4 signaling is an important mechanism by which host cells detect the presence of LPS and other indicators of bacterial infections. Our results suggest that mitochondria and multiple P2 receptor subtypes are involved in the host immune responses to bacterial infection. LPS was shown to promote the polarization of monocytes toward an inflammatory phenotype that relies mainly on aerobic glycolysis (41) . On the other hand, mitochondria require oxygen for ATP production, which suggests that hypoxic conditions as well as changes in the metabolic environment that impair TLR signaling and IL-1β production could impair the ability of monocytes and macrophages to defend the host from infections. This possibility is supported by our findings that panx1 knockout mice failed to produce IL-1β and to effectively protect the host from bacterial infection. We conclude that the purinergic signaling mechanisms identified in our study are potential novel targets to modulate inflammation and host responses in critical care patients. , and human monocytes (IL-1β) were stimulated for 24 hr with lipopolysaccharides (LPS) (10 ng/mL) in the presence or absence of carbenoxolone (CBX) (100 μM) or suramin (200 μM) and cell activation was measured by immunoblotting or enzyme-linked immunosorbent assay (ELISA) (IL-1β). Data are means ± sd, n = 3; *p < 0.05 vs LPSstimulated controls. B, C57BL/6 wild-type (WT) mice were subjected to sepsis using cecal ligation and puncture (CLP) and plasma IL-1β levels as well as CD11b and Ly6C expression by peripheral blood monocytes were measured by ELISA and flow cytometry, respectively, at the time points indicated. C, WT mice or panx1 knockout (KO) mice were subjected to CLP or sham surgery, and IL-1β plasma levels and the increase in inflammatory Ly6C ++ M1 monocytes were determined 4 hr after CLP and compared with sham animals (left). WT or panx1 KO mice were injected intraperitoneal with 1 × 10 8 live Escherichia coli and bacteria in the peritoneal cavity were counted 2 hr later (right). Data are expressed as mean ± sem of n = 5 animals per group; *p < 0.05. CFU = colony forming units, MFI = mean fluorescence intensity.
